...
search icon
xfor-img

X4 Pharmaceuticals Inc, Common Stock

XFOR

NAQ

$2.71

-$0.21

(-7.19%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$19.16M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
1.3839
Volume info-icon
This is the total number of shares traded during the most recent trading day.
321.32K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.73
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.84 L
$33.9 H
$2.71

About X4 Pharmaceuticals Inc, Common Stock

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameXFORSectorS&P500
1-Week Return-18.13%1.9%1.37%
1-Month Return-52.2%1.36%15.76%
3-Month Return-80.9%-8.73%-2.58%
6-Month Return-73.43%-5.96%0.72%
1-Year Return-89.96%-7.97%12.24%
3-Year Return-92.21%3.54%52.73%
5-Year Return-98.99%34.17%100.37%
10-Year Return-99.89%78.8%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue3.00M---2.56M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":85.23,"profit":true}]
Cost of Revenue-1.89M1.99M2.00M797.00K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":94.79,"profit":true},{"date":"2022-12-31","value":99.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":39.93,"profit":true}]
Gross Profit3.00M(1.89M)(1.99M)(2.00M)1.76M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-63.07,"profit":false},{"date":"2022-12-31","value":-66.47,"profit":false},{"date":"2023-12-31","value":-66.53,"profit":false},{"date":"2024-12-31","value":58.67,"profit":true}]
Gross Margin100.00%(Infinity%)(Infinity%)(Infinity%)68.83%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":68.83,"profit":true}]
Operating Expenses62.87M75.35M88.08M107.52M38.16M[{"date":"2020-12-31","value":58.48,"profit":true},{"date":"2021-12-31","value":70.08,"profit":true},{"date":"2022-12-31","value":81.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":35.49,"profit":true}]
Operating Income(59.87M)(85.11M)(87.57M)(107.52M)(36.40M)[{"date":"2020-12-31","value":-5987400000,"profit":false},{"date":"2021-12-31","value":-8510700000,"profit":false},{"date":"2022-12-31","value":-8756900000,"profit":false},{"date":"2023-12-31","value":-10752200000,"profit":false},{"date":"2024-12-31","value":-3640100000,"profit":false}]
Total Non-Operating Income/Expense(4.52M)(7.20M)(10.04M)4.73M(3.74M)[{"date":"2020-12-31","value":-95.58,"profit":false},{"date":"2021-12-31","value":-152.21,"profit":false},{"date":"2022-12-31","value":-212.21,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-78.98,"profit":false}]
Pre-Tax Income(61.98M)(88.68M)(93.84M)(101.09M)(37.14M)[{"date":"2020-12-31","value":-6198300000,"profit":false},{"date":"2021-12-31","value":-8867900000,"profit":false},{"date":"2022-12-31","value":-9383900000,"profit":false},{"date":"2023-12-31","value":-10108900000,"profit":false},{"date":"2024-12-31","value":-3714000000,"profit":false}]
Income Taxes148.00K17.00K28.00K78.00K310.00K[{"date":"2020-12-31","value":47.74,"profit":true},{"date":"2021-12-31","value":5.48,"profit":true},{"date":"2022-12-31","value":9.03,"profit":true},{"date":"2023-12-31","value":25.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(62.13M)(88.70M)(93.87M)(101.17M)(37.45M)[{"date":"2020-12-31","value":-6213100000,"profit":false},{"date":"2021-12-31","value":-8869600000,"profit":false},{"date":"2022-12-31","value":-9386700000,"profit":false},{"date":"2023-12-31","value":-10116700000,"profit":false},{"date":"2024-12-31","value":-3745000000,"profit":false}]
Income From Continuous Operations(62.13M)(88.70M)(93.87M)(111.14M)(37.45M)[{"date":"2020-12-31","value":-6213100000,"profit":false},{"date":"2021-12-31","value":-8869600000,"profit":false},{"date":"2022-12-31","value":-9386700000,"profit":false},{"date":"2023-12-31","value":-11114100000,"profit":false},{"date":"2024-12-31","value":-3745000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(62.13M)(88.70M)(93.87M)(101.17M)(37.45M)[{"date":"2020-12-31","value":-6213100000,"profit":false},{"date":"2021-12-31","value":-8869600000,"profit":false},{"date":"2022-12-31","value":-9386700000,"profit":false},{"date":"2023-12-31","value":-10116700000,"profit":false},{"date":"2024-12-31","value":-3745000000,"profit":false}]
EPS (Diluted)(2.97)(3.70)(1.87)(0.60)(0.71)[{"date":"2020-12-31","value":-297,"profit":false},{"date":"2021-12-31","value":-370,"profit":false},{"date":"2022-12-31","value":-187,"profit":false},{"date":"2023-12-31","value":-60,"profit":false},{"date":"2024-12-31","value":-71,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

XFOR
Cash Ratio 3.36
Current Ratio 3.70
Quick Ratio 3.58

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

XFOR
ROA (LTM) -58.61%
ROE (LTM) 121.75%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

XFOR
Debt Ratio Lower is generally better. Negative is bad. 0.82
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.18

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

XFOR
Trailing PE 1.38
Forward PE NM
P/S (TTM) 0.54
P/B 0.74
Price/FCF NM
EV/R 0.25
EV/Ebitda 0.32

FAQs

What is X4 Pharmaceuticals Inc share price today?

X4 Pharmaceuticals Inc (XFOR) share price today is $2.71

Can Indians buy X4 Pharmaceuticals Inc shares?

Yes, Indians can buy shares of X4 Pharmaceuticals Inc (XFOR) on Vested. To buy X4 Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XFOR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of X4 Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of X4 Pharmaceuticals Inc (XFOR) via the Vested app. You can start investing in X4 Pharmaceuticals Inc (XFOR) with a minimum investment of $1.

How to invest in X4 Pharmaceuticals Inc shares from India?

You can invest in shares of X4 Pharmaceuticals Inc (XFOR) via Vested in three simple steps:

  • Click on Sign Up or Invest in XFOR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in X4 Pharmaceuticals Inc shares
What is X4 Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of X4 Pharmaceuticals Inc (XFOR) is $33.9. The 52-week low price of X4 Pharmaceuticals Inc (XFOR) is $2.84.

What is X4 Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of X4 Pharmaceuticals Inc (XFOR) is 1.3839

What is X4 Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of X4 Pharmaceuticals Inc (XFOR) is 0.74

What is the Market Cap of X4 Pharmaceuticals Inc?

The market capitalization of X4 Pharmaceuticals Inc (XFOR) is $19.16M

What is X4 Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of X4 Pharmaceuticals Inc is XFOR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top